Top

Published in:

01-12-2013 | Molecular Biology (S Anant, Section Editor)

Reactive Oxygen Species and Colorectal Cancer

Authors: Sandeep Sreevalsan, Stephen Safe

Published in: Current Colorectal Cancer Reports | Issue 4/2013

Abstract

Several agents used for treatment of colon and other cancers induce reactive oxygen species (ROS), and this plays an important role in their anticancer activities. In addition to the well-known proapoptotic effects of ROS inducers, these compounds also decrease expression of specificity protein (Sp) transcription factors Sp1, Sp3, and Sp4 and several prooncogenic Sp-regulated genes important for cancer cell proliferation, survival, and metastasis. The mechanism of these responses involves ROS-dependent downregulation of miR-27a or miR-20a (and paralogs) and induction of two Sp repressors, ZBTB10 and ZBTB4, respectively. This pathway significantly contributes to the anticancer activity of ROS inducers and should be considered in the development of drug combinations for cancer chemotherapy.

Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer incidence and mortality worldwide. 2010. Available from http://globocan.iarc.fr. Accessed 17 Jul 2012.

Boyle P, Levin B, editors. World cancer report 2008. Lyon: IARC; 2008. p. 15.

Jemal A et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRef

Curado MP, Edwards B, Shin HR. Cancer incidence in five continents. Vol. IX. Lyon: IARC; 2007.

Parkin DM et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.PubMedCrossRef

Chan AT, Giovannucci EL. Primary prevention of colorectal cancer. Gastroenterology. 2010;138(6):2029–2043.PubMedCrossRef

Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 2009;18(6):1688–94.PubMedCrossRef

La Vecchia C et al. Dietary total antioxidant capacity and colorectal cancer: a large case–control study in Italy. Int J Cancer. 2013;27(10):28133.

Bird CL et al. Plasma ferritin, iron intake, and the risk of colorectal polyps. Am J Epidemiol. 1996;144(1):34–41.PubMedCrossRef

10.

Stevens RG et al. Body iron stores and the risk of cancer. N Engl J Med. 1988;319(16):1047–52.PubMedCrossRef

11.

• Dickinson BC, Chang CJ. Chemistry and biology of reactive oxygen species in signaling or stress responses. Nat Chem Biol. 2011;7(8):504–11. This review outlines the diverse roles (physiological and pathological) that ROS play in various tissue and organ systems.PubMedCrossRef

12.

Hancock JT, Desikan R, Neill SJ. Role of reactive oxygen species in cell signalling pathways. Biochem Soc Trans. 2001;29(Pt 2):345–50.PubMedCrossRef

13.

Afanas'ev I. Reactive oxygen species signaling in cancer: comparison with aging. Aging Dis. 2011;2(3):219–30.PubMed

14.

Kumar B et al. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res. 2008;68(6):1777–85.PubMedCrossRef

15.

Vaquero EC et al. Reactive oxygen species produced by NAD(P)H oxidase inhibit apoptosis in pancreatic cancer cells. J Biol Chem. 2004;279(33):34643–54.PubMedCrossRef

16.

Waris G, Ahsan H. Reactive oxygen species: role in the development of cancer and various chronic conditions. J Carcinog. 2006;5:14.PubMedCrossRef

17.

Gupta SC et al. Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal. 2012;16(11):1295–322.PubMedCrossRef

18.

Martindale JL, Holbrook NJ. Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol. 2002;192(1):1–15.PubMedCrossRef

19.

Medan D et al. Regulation of Fas (CD95)-induced apoptotic and necrotic cell death by reactive oxygen species in macrophages. J Cell Physiol. 2005;203(1):78–84.PubMedCrossRef

20.

Shrivastava A et al. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Mol Cancer Ther. 2011;10(7):1161–72.PubMedCrossRef

21.

Coriat R et al. The organotelluride catalyst LAB027 prevents colon cancer growth in the mice. Cell Death Dis. 2011;2:e191.PubMedCrossRef

22.

Donadelli M et al. Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Cell Death Dis. 2011;28(2):36.

23.

Chen Y et al. Oxidative stress induces autophagic cell death independent of apoptosis in transformed and cancer cells. Cell Death Differ. 2008;15(1):171–82.PubMedCrossRef

24.

Li J et al. Tephrosin-induced autophagic cell death in A549 non-small cell lung cancer cells. J Asian Nat Prod Res. 2010;12(11):992–1000.PubMedCrossRef

25.

Garbarino JA et al. Demalonyl thyrsiflorin A, a semisynthetic labdane-derived diterpenoid, induces apoptosis and necrosis in human epithelial cancer cells. Chem Biol Interact. 2007;169(3):198–206.PubMedCrossRef

26.

Kim JS et al. Role of reactive oxygen species-mediated mitochondrial dysregulation in 3-bromopyruvate induced cell death in hepatoma cells: ROS-mediated cell death by 3-BrPA. J Bioenerg Biomembr. 2008;40(6):607–18.PubMedCrossRef

27.

Nair RR et al. HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells. Mol Cancer Ther. 2009;8(8):2441–51.PubMedCrossRef

28.

Naito M et al. Caspase-independent necrotic cell death induced by a radiosensitizer, 8-nitrocaffeine. Cancer Sci. 2004;95(4):361–6.PubMedCrossRef

29.

Yogosawa S et al. Dehydrozingerone, a structural analogue of curcumin, induces cell-cycle arrest at the G2/M phase and accumulates intracellular ROS in HT-29 human colon cancer cells. J Nat Prod. 2012;75(12):2088–93.PubMedCrossRef

30.

Noratto GD et al. The drug resistance suppression induced by curcuminoids in colon cancer SW-480 cells is mediated by reactive oxygen species-induced disruption of the microRNA-27a-ZBTB10-Sp axis. Mol Nutr Food Res. 2013;8(10):201200609.

31.

Shehzad A et al. Curcumin induces apoptosis in human colorectal carcinoma (HCT-15) cells by regulating expression of Prp4 and p53. Mol Cells. 2013;16:16.

32.

Dinicola S et al. Grape seed extract triggers apoptosis in Caco-2 human colon cancer cells through reactive oxygen species and calcium increase: extracellular signal-regulated kinase involvement. Br J Nutr. 2013;25:1–13.

33.

Papi A et al. Vitexin-2-O-xyloside, raphasatin and (−)-epigallocatechin-3-gallate synergistically affect cell growth and apoptosis of colon cancer cells. Food Chem. 2013;138(2–3):1521–30.PubMedCrossRef

34.

Yang F et al. Hirsutanol A, a novel sesquiterpene compound from fungus Chondrostereum sp., induces apoptosis and inhibits tumor growth through mitochondrial-independent ROS production: hirsutanol A inhibits tumor growth through ROS production. J Transl Med. 2013;11(32):1479–5876.

35.

Pierre AS et al. Trans-10, cis-12 conjugated linoleic acid induced cell death in human colon cancer cells through reactive oxygen species-mediated ER stress. Biochim Biophys Acta. 2013;4:759–68.

36.

Thomasz L et al. 6 iodo-delta-lactone: a derivative of arachidonic acid with antitumor effects in HT-29 colon cancer cells. Prostaglandins Leukot Essent Fat Acids. 2013;88(4):273–80.CrossRef

37.

Maillet A et al. A novel osmium-based compound targets the mitochondria and triggers ROS-dependent apoptosis in colon carcinoma. Cell Death Dis. 2013;6(4):185.

38.

Lupidi G et al. Synthesis, properties, and antitumor effects of a new mixed phosphine gold(I) compound in human colon cancer cells. J Inorg Biochem. 2013;124:78–87.PubMedCrossRef

39.

Sun L et al. Reactive oxygen species mediate Cr(VI)-induced S phase arrest through p53 in human colon cancer cells. J Environ Pathol Toxicol Oncol. 2012;31(2):95–107.PubMedCrossRef

40.

Chintharlapalli S et al. Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and -independent downregulation of specificity proteins (Sp) transcription factors. BMC Cancer. 2011;11:371.PubMedCrossRef

41.

• Gandhy SU et al. Curcumin and synthetic analogs induce reactive oxygen species and decreases specificity protein (Sp) transcription factors by targeting microRNAs. BMC Cancer. 2012;12(564):1471–2407. The authors demonstrate the role of the zinc finger ZBTB4 and microRNAs from miR-17-92 clusters in Sp transcription factor regulation in colon cancer and show a novel mechanism by which curcumin and its structural analogs downregulate Sp proteins through induction of ROS and disruption the miR-20a–miR-17-5-p–ZBTB4 axis.

42.

• Pathi SS et al. GT-094, a NO-NSAID, inhibits colon cancer cell growth by activation of a reactive oxygen species-microRNA-27a: ZBTB10-specificity protein pathway. Mol Cancer Res. 2011;9(2):195–202. This study for the first time shows drug-mediated ROS-dependent disruption of the miR27a–ZBTB10 axis in colon cancer cells leading to downregulation of Sp transcription factors that are involved in cancer cell growth, survival, and metastasis.PubMedCrossRef

43.

Pathi SS et al. Pharmacologic doses of ascorbic acid repress specificity protein (Sp) transcription factors and Sp-regulated genes in colon cancer cells. Nutr Cancer. 2011;63(7):1133–42.PubMedCrossRef

44.

Suske G. The Sp-family of transcription factors. Gene. 1999;238(2):291–300.PubMedCrossRef

45.

Gidoni D et al. Bidirectional SV40 transcription mediated by tandem Sp1 binding interactions. Science. 1985;230(4725):511–7.PubMedCrossRef

46.

Giglioni B et al. The same nuclear proteins bind the proximal CACCC box of the human β-globin promoter and a similar sequence in the enhancer. Biochem Biophys Res Commun. 1989;164(1):149–55.PubMedCrossRef

47.

Imataka H et al. Two regulatory proteins that bind to the basic transcription element (BTE), a GC box sequence in the promoter region of the rat P-4501A1 gene. EMBO J. 1992;11(10):3663–71.PubMed

48.

Abdelrahim M, Safe S. Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins. Mol Pharmacol. 2005;68(2):317–29.PubMed

49.

Abdelrahim M et al. Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst. 2006;98(12):855–68.PubMedCrossRef

50.

Chintharlapalli S et al. Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res. 2007;67(6):2816–23.PubMedCrossRef

51.

Chadalapaka G et al. Curcumin decreases specificity protein expression in bladder cancer cells. Cancer Res. 2008;68(13):5345–54.PubMedCrossRef

52.

Mertens-Talcott SU et al. The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res. 2007;67(22):11001–11.PubMedCrossRef

53.

Safe S, Abdelrahim M. Sp transcription factor family and its role in cancer. Eur J Cancer. 2005;41(16):2438–48.PubMedCrossRef

54.

Abdelrahim M et al. Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells. Cancer Res. 2007;67(7):3286–94.PubMedCrossRef

55.

Higgins KJ et al. Regulation of vascular endothelial growth factor receptor-2 expression in pancreatic cancer cells by Sp proteins. Biochem Biophys Res Commun. 2006;345(1):292–301.PubMedCrossRef

56.

Abdelrahim M et al. Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res. 2004;64(18):6740–9.PubMedCrossRef

57.

Bouwman P, Philipsen S. Regulation of the activity of Sp1-related transcription factors. Mol Cell Endocrinol. 2002;195(1–2):27–38.PubMedCrossRef

58.

Black AR, Black JD, Azizkhan-Clifford J. Sp1 and krüppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol. 2001;188(2):143–60.PubMedCrossRef

59.

Ammendola R et al. Sp1 DNA binding efficiency is highly reduced in nuclear extracts from aged rat tissues. J Biol Chem. 1992;267(25):17944–8.PubMed

60.

Adrian GS et al. YY1 and Sp1 transcription factors bind the human transferrin gene in an age-related manner. J Gerontol A Biol Sci Med Sci. 1996;51(1):B66–75.PubMedCrossRef

61.

Oh JE, Han JA, Hwang ES. Downregulation of transcription factor, Sp1, during cellular senescence. Biochem Biophys Res Commun. 2007;353(1):86–91.PubMedCrossRef

62.

• Jutooru I et al. Arsenic trioxide downregulates specificity protein (Sp) transcription factors and inhibits bladder cancer cell and tumor growth. Exp Cell Res. 2010;316(13):2174–88. This study establishes the role of ROS in downregulation of Sp transcription factors and Sp-regulated genes important in cancer cell proliferation, growth, and survival in bladder cancer and several other cancer cell types.PubMedCrossRef

63.

Tillotson LG. RIN ZF, a novel zinc finger gene, encodes proteins that bind to the CACC element of the gastrin promoter. J Biol Chem. 1999;274(12):8123–8.PubMedCrossRef

64.

Scott GK et al. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res. 2006;66(3):1277–81.PubMedCrossRef

65.

Weber A et al. Zbtb4 represses transcription of P21CIP1 and controls the cellular response to p53 activation. EMBO J. 2008;27(11):1563–74.PubMedCrossRef

66.

•• Kim K et al. Identification of oncogenic microRNA-17-92/ZBTB4/specificity protein axis in breast cancer. Oncogene. 2012;31(8):1034–44. The authors demonstrate a novel mechanism of Sp regulation by microRNAs derived from the miR-17-92 cluster, which suppresses the expression of an Sp repressor, ZBTB4.PubMedCrossRef

67.

•• O'Hagan HM et al. Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG islands. Cancer Cell. 2011;20(5):606–19. The authors demonstrate that oxidative damage can cause recruiting of silencing complexes containing DNA methyltransferases from the non-GC-rich or transcriptionally poor regions of the genome to GC-rich regions of the genome, which explains global hypomethylation that is commonly observed in cancer.PubMedCrossRef

Title: Reactive Oxygen Species and Colorectal Cancer
Authors: Sandeep Sreevalsan
Stephen Safe
Publication date: 01-12-2013
Publisher: Springer US
Published in: Current Colorectal Cancer Reports / Issue 4/2013
Print ISSN: 1556-3790
Electronic ISSN: 1556-3804
DOI: https://doi.org/10.1007/s11888-013-0190-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2013

The Clinical Potential of Circulating Tumor Cells and Circulating Tumor-Associated Cellular Elements in Colorectal Cancer

Stem Cell Signaling Pathways in Colorectal Cancer

Role of Apoptosis in Colon Cancer Biology, Therapy, and Prevention

Honokiol as a Radiosensitizing Agent for Colorectal Cancers

Status of Active Specific Immunotherapy for Stage II, Stage III, and Resected Stage IV Colon Cancer

Oncotype DX for Colon Cancer: Are We Ready for Prime Time in Personalized Medicine?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer